|
US266710A
(en)
|
|
1882-10-31 |
|
Fastening for pocket-books |
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4275149A
(en)
|
1978-11-24 |
1981-06-23 |
Syva Company |
Macromolecular environment control in specific receptor assays
|
|
US4318980A
(en)
|
1978-04-10 |
1982-03-09 |
Miles Laboratories, Inc. |
Heterogenous specific binding assay employing a cycling reactant as label
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
US4419446A
(en)
|
1980-12-31 |
1983-12-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant DNA process utilizing a papilloma virus DNA as a vector
|
|
NZ201705A
(en)
|
1981-08-31 |
1986-03-14 |
Genentech Inc |
Recombinant dna method for production of hepatitis b surface antigen in yeast
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
US4601978A
(en)
|
1982-11-24 |
1986-07-22 |
The Regents Of The University Of California |
Mammalian metallothionein promoter system
|
|
US4560655A
(en)
|
1982-12-16 |
1985-12-24 |
Immunex Corporation |
Serum-free cell culture medium and process for making same
|
|
US4657866A
(en)
|
1982-12-21 |
1987-04-14 |
Sudhir Kumar |
Serum-free, synthetic, completely chemically defined tissue culture media
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
DD266710A3
(de)
|
1983-06-06 |
1989-04-12 |
Ve Forschungszentrum Biotechnologie |
Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
|
|
US4767704A
(en)
|
1983-10-07 |
1988-08-30 |
Columbia University In The City Of New York |
Protein-free culture medium
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
|
US4879231A
(en)
|
1984-10-30 |
1989-11-07 |
Phillips Petroleum Company |
Transformation of yeasts of the genus pichia
|
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
|
DE3675588D1
(de)
|
1985-06-19 |
1990-12-20 |
Ajinomoto Kk |
Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
|
|
GB8516415D0
(en)
|
1985-06-28 |
1985-07-31 |
Celltech Ltd |
Culture of animal cells
|
|
US4927762A
(en)
|
1986-04-01 |
1990-05-22 |
Cell Enterprises, Inc. |
Cell culture medium with antioxidant
|
|
GB8610600D0
(en)
|
1986-04-30 |
1986-06-04 |
Novo Industri As |
Transformation of trichoderma
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
AU632065B2
(en)
|
1988-09-23 |
1992-12-17 |
Novartis Vaccines And Diagnostics, Inc. |
Cell culture medium for enhanced cell growth, culture longevity and product expression
|
|
FR2646437B1
(fr)
|
1989-04-28 |
1991-08-30 |
Transgene Sa |
Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
|
|
EP0402226A1
(en)
|
1989-06-06 |
1990-12-12 |
Institut National De La Recherche Agronomique |
Transformation vectors for yeast yarrowia
|
|
US5122469A
(en)
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
JP4124480B2
(ja)
|
1991-06-14 |
2008-07-23 |
ジェネンテック・インコーポレーテッド |
免疫グロブリン変異体
|
|
ATE139900T1
(de)
|
1992-11-13 |
1996-07-15 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US6037454A
(en)
|
1996-11-27 |
2000-03-14 |
Genentech, Inc. |
Humanized anti-CD11a antibodies
|
|
US5888809A
(en)
|
1997-05-01 |
1999-03-30 |
Icos Corporation |
Hamster EF-1α transcriptional regulatory DNA
|
|
US6737056B1
(en)
*
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6808710B1
(en)
|
1999-08-23 |
2004-10-26 |
Genetics Institute, Inc. |
Downmodulating an immune response with multivalent antibodies to PD-1
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
EP1445264B1
(en)
|
2001-07-31 |
2011-09-14 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to pd-1
|
|
JP4511943B2
(ja)
|
2002-12-23 |
2010-07-28 |
ワイス エルエルシー |
Ｐｄ−１に対する抗体およびその使用
|
|
EP2270051B1
(en)
|
2003-01-23 |
2019-05-15 |
Ono Pharmaceutical Co., Ltd. |
Antibody specific for human PD-1 and CD3
|
|
CA2554089C
(en)
|
2004-02-09 |
2013-10-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
PL2161336T5
(pl)
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
|
WO2009026472A1
(en)
|
2007-08-21 |
2009-02-26 |
The General Hospital Corporation |
Methods for inducing tolerance
|
|
EP2225397A4
(en)
|
2007-11-28 |
2011-08-17 |
Univ Montreal |
PD-1 MODULATION AND USES THEREOF
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
EP2342228B1
(en)
|
2008-09-12 |
2017-09-06 |
Oxford University Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
|
CA2736829C
(en)
|
2008-09-12 |
2018-02-27 |
Isis Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
|
CA2998281C
(en)
|
2008-09-26 |
2022-08-16 |
Dana-Farber Cancer Institute, Inc. |
Human anti-pd-1 antobodies and uses therefor
|
|
US8993731B2
(en)
|
2010-03-11 |
2015-03-31 |
Ucb Biopharma Sprl |
PD-1 antibody
|
|
TW201134488A
(en)
*
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
AR083044A1
(es)
|
2010-09-27 |
2013-01-30 |
Regeneron Pharma |
Anticuerpos anti-cd48 y usos de los mismos
|
|
US9683054B2
(en)
|
2010-12-31 |
2017-06-20 |
BioAlta, LLC |
Express humanization of antibodies
|
|
US9701749B2
(en)
|
2011-08-11 |
2017-07-11 |
Ono Pharmaceutical Co., Ltd. |
Therapeutic agent for autoimmune diseases comprising PD-1 agonist
|
|
HUE053069T2
(hu)
|
2013-05-02 |
2021-06-28 |
Anaptysbio Inc |
Programozott halál-1 (PD-1) ellen irányuló ellenanyagok
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
US10077305B2
(en)
|
2013-09-10 |
2018-09-18 |
Medimmune Limited |
Antibodies against PD-1 and uses thereof
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
CN105330740B
(zh)
*
|
2014-07-30 |
2018-08-17 |
珠海市丽珠单抗生物技术有限公司 |
抗pd-1抗体及其应用
|
|
SG11201700672YA
(en)
|
2014-08-05 |
2017-02-27 |
MabQuest SA |
Immunological reagents binding to pd-1
|
|
TWI595006B
(zh)
*
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
CA2971734C
(en)
|
2014-12-22 |
2025-11-18 |
Enumeral Biomedical Holdings Inc |
Anti-pd-1 antibodies
|
|
TWI773647B
(zh)
|
2015-06-23 |
2022-08-11 |
史隆凱特林紀念癌症中心 |
新穎pd-1免疫調控劑
|
|
CN106699888B
(zh)
|
2015-07-28 |
2020-11-06 |
上海昀怡健康科技发展有限公司 |
一种pd-1抗体及其制备方法和应用
|
|
WO2017058859A1
(en)
|
2015-09-29 |
2017-04-06 |
Celgene Corporation |
Pd-1 binding proteins and methods of use thereof
|
|
CA3000564A1
(en)
|
2015-10-02 |
2017-04-06 |
Symphogen A/S |
Anti-pd-1 antibodies and compositions
|
|
KR102072317B1
(ko)
|
2015-10-02 |
2020-01-31 |
에프. 호프만-라 로슈 아게 |
항-pd1 항체 및 사용 방법
|
|
WO2017079080A1
(en)
|
2015-11-02 |
2017-05-11 |
The Johns Hopkins University |
Method of preventing organ transplant rejections using agonists to the pd-1 checkpoint pathway
|
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技（上海）有限公司 |
抗pd-1抗体及其治疗用途
|
|
US10759859B2
(en)
|
2016-01-14 |
2020-09-01 |
Bps Bioscience, Inc. |
Anti-PD-1 antibodies and uses thereof
|
|
US11299751B2
(en)
*
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
JP2019528082A
(ja)
|
2016-06-08 |
2019-10-10 |
シャンハイ ジャオ トン ユニバーシティ スクール オブ メディシン |
アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
|
|
RU2656181C1
(ru)
|
2016-07-13 |
2018-05-31 |
Закрытое Акционерное Общество "Биокад" |
Анти-pd-1-антитела, способ их получения и способ применения
|
|
MX2019002946A
(es)
*
|
2016-09-14 |
2019-09-26 |
Abbvie Biotherapeutics Inc |
Anticuerpos anti-pd-1 y sus usos.
|
|
EA201990672A1
(ru)
|
2016-09-14 |
2019-08-30 |
Бэйцзин Ханми Фарм. Ко., Лтд. |
Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
|
|
CN109952317A
(zh)
|
2016-09-19 |
2019-06-28 |
细胞基因公司 |
使用pd-1结合蛋白治疗免疫病症的方法
|
|
JP2019534859A
(ja)
|
2016-09-19 |
2019-12-05 |
セルジーン コーポレイション |
Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
|
|
DK3515938T3
(da)
|
2016-09-21 |
2025-04-07 |
Cstone Pharmaceuticals |
Monoklonale antistoffer mod programmeret død 1 (pd-1)
|
|
CN107840887B
(zh)
|
2016-09-21 |
2022-03-25 |
基石药业（苏州）有限公司 |
一种新的pd-1单克隆抗体
|
|
MA46724A
(fr)
|
2016-11-01 |
2021-04-21 |
Anaptysbio Inc |
Anticorps dirigés contre la mort programmée 1 (pd -1)
|
|
HUE057559T2
(hu)
|
2016-11-02 |
2022-06-28 |
Jounce Therapeutics Inc |
PD-1 elleni antitestek és alkalmazásaik
|
|
WO2018091661A1
(en)
|
2016-11-18 |
2018-05-24 |
Symphogen A/S |
Anti-pd-1 antibodies and compositions
|
|
CN106519034B
(zh)
|
2016-12-22 |
2020-09-18 |
鲁南制药集团股份有限公司 |
抗pd-1抗体及其用途
|
|
CN110167966B
(zh)
|
2017-01-06 |
2024-08-30 |
克雷森多生物制剂有限公司 |
程序性细胞死亡(pd-1)的单结构域抗体
|
|
MA47208A
(fr)
|
2017-01-09 |
2019-11-13 |
Tesaro Inc |
Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
|
|
WO2018136553A1
(en)
|
2017-01-18 |
2018-07-26 |
Genentech, Inc. |
Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
|
|
CN110382536B
(zh)
*
|
2017-01-20 |
2023-12-19 |
大有华夏生物医药集团有限公司 |
抗pd-1抗体及其用途
|
|
CN108341871A
(zh)
|
2017-01-24 |
2018-07-31 |
三生国健药业（上海）股份有限公司 |
抗pd-1单克隆抗体及其制备方法和应用
|
|
MX2019010999A
(es)
|
2017-03-29 |
2020-02-05 |
Celgene Corp |
Formulaciones que comprenden proteinas de union a pd-1 y metodos para preparar las mismas.
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
CR20190550A
(es)
|
2017-06-05 |
2020-04-05 |
Janssen Biotech Inc |
Anticuerpos que se unen específicamente a pd-1 y métodos de uso
|
|
WO2018223923A1
(zh)
|
2017-06-05 |
2018-12-13 |
江苏恒瑞医药股份有限公司 |
Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
|
|
SI3661954T1
(sl)
|
2017-08-03 |
2022-05-31 |
Amgen Inc. |
Muteini interlevkina-21 in postopki zdravljenja
|
|
UY38049A
(es)
|
2018-01-12 |
2019-07-31 |
Amgen Inc |
Anti-pd-1 anticuerpos y métodos de tratamiento
|
|
AR114127A1
(es)
|
2018-03-02 |
2020-07-22 |
Lilly Co Eli |
Anticuerpos agonistas contra pd-1 y usos de estos
|
|
IL277095B2
(en)
|
2018-03-07 |
2025-10-01 |
Pfizer |
Preparations containing anti-PD-1 antibody
|
|
GB201803745D0
(en)
|
2018-03-08 |
2018-04-25 |
Ultrahuman Eight Ltd |
PD1 binding agents
|
|
GB201803746D0
(en)
|
2018-03-08 |
2018-04-25 |
Ultrahuman Eight Ltd |
PD1 binding agents
|
|
WO2019179421A1
(en)
|
2018-03-19 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Novel bispecific pd-1/ctla-4 antibody molecules
|
|
WO2019179390A1
(en)
|
2018-03-19 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Novel bispecific pd-1/egfr antibody molecules
|
|
WO2019179391A1
(en)
|
2018-03-19 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Novel bispecific pd-1/ctla-4 antibody molecules
|
|
WO2019179434A1
(en)
|
2018-03-20 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Novel bispecific pd-1/cd47 antibody molecules
|
|
CA3093992A1
(en)
|
2018-03-20 |
2019-09-26 |
WuXi Biologics Ireland Limited |
Novel anti-pd-1 antibodies
|
|
WO2019219064A1
(en)
|
2018-05-17 |
2019-11-21 |
Nanjing Leads Biolabs Co.Ltd |
Antibody binding pd-1 and use thereof
|
|
US12258407B2
(en)
|
2018-07-19 |
2025-03-25 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Anti-PD-1 antibodies, dosages and uses thereof
|
|
CN113861295B
(zh)
*
|
2018-07-20 |
2024-05-24 |
厦门大学 |
抗pd-1抗体及其用途
|
|
EP3876978A4
(en)
|
2018-11-07 |
2022-09-28 |
Merck Sharp & Dohme Corp. |
STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
|
|
US12234289B2
(en)
|
2018-12-07 |
2025-02-25 |
Ono Pharmaceutical Co., Ltd. |
Immunosuppresive agent
|
|
TWI862565B
(zh)
|
2019-04-04 |
2024-11-21 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
CN110577599A
(zh)
|
2019-05-13 |
2019-12-17 |
深圳市润科生物科技有限公司 |
人源抗程序性死亡-1(pd-1)抗体及其应用
|
|
WO2020247648A2
(en)
|
2019-06-05 |
2020-12-10 |
Anaptysbio, Inc. |
Pd-1 agonist and method of using same
|
|
KR20220042257A
(ko)
|
2019-07-12 |
2022-04-04 |
더 존스 홉킨스 유니버시티 |
뇌 혈관연축을 치료하기 위한 조성물 및 방법
|
|
EP4011918A4
(en)
|
2019-08-08 |
2023-08-23 |
ONO Pharmaceutical Co., Ltd. |
DUAL SPECIFIC PROTEIN
|
|
TW202124437A
(zh)
|
2019-08-19 |
2021-07-01 |
美商潘迪恩營運公司 |
以ｐｄ－１促效劑進行之標靶免疫耐受性
|
|
WO2021121373A1
(zh)
|
2019-12-20 |
2021-06-24 |
广东菲鹏制药股份有限公司 |
抗人程序死亡因子-1单克隆抗体
|
|
EP4076385B1
(en)
|
2019-12-20 |
2025-12-10 |
Formycon AG |
Formulations of anti-pd1 antibodies
|
|
CN110787292B
(zh)
|
2020-01-06 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
一种细胞程序性死亡受体1抗体制剂及其用途
|
|
KR20210097882A
(ko)
|
2020-01-30 |
2021-08-10 |
삼성바이오에피스 주식회사 |
안정한 항-pd-1 항체 약제학적 제제
|
|
CN113456582B
(zh)
|
2020-03-30 |
2024-06-14 |
鲁南制药集团股份有限公司 |
重组人源化抗pd-1单克隆抗体的液体制剂
|
|
EP4159235A4
(en)
|
2020-05-25 |
2024-07-10 |
Foundation for Biomedical Research and Innovation at Kobe |
PHARMACEUTICAL COMPOSITION CONTAINING PD-1 AGONIST FOR TREATING OR PREVENTING TH2-MEDIATED DISEASE
|
|
PL4157876T3
(pl)
|
2020-05-26 |
2025-02-03 |
Boehringer Ingelheim International Gmbh |
Przeciwciała anty-pd-1
|
|
CN113797330A
(zh)
|
2020-06-11 |
2021-12-17 |
三生国健药业（上海）股份有限公司 |
一种抗pd-1单克隆抗体液体制剂
|
|
KR20230026446A
(ko)
|
2020-06-19 |
2023-02-24 |
사이노셀테크 엘티디. |
재조합 항-pd-1 단일클론 항체를 위한 안정한 제형
|
|
CN111956799A
(zh)
|
2020-09-18 |
2020-11-20 |
生物抗素公司 |
抗pd-1抗体和/或pd-l1抗体在制备治疗帕金森病药物中的应用
|